Comparing pediatric neuroblastoma patients treated with Dinutuximab at two French hospitals
Dinutuximab Beta at the Strasbourg University Hospitals (HUS) and the Toulouse Oncopole: Comparative Analysis of Patient Pathways, Associated Costs and Quality of Life According to Traditional Hospitalization or Hospital at Home (HAD)
This study looks at how children and young adults with neuroblastoma are treated with Dinutuximab at two hospitals in France to see how the costs and quality of life compare between them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 2 Years to 25 Years |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Drugs / interventions | Dinutuximab |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06275334 on ClinicalTrials.gov |
What this trial studies
This observational study aims to describe a cohort of pediatric patients suffering from neuroblastoma who are treated with Dinutuximab at the University Hospital of Strasbourg and the Oncopole of Toulouse. The study will compare the costs and quality of life outcomes between these two treatment centers. It includes patients aged 2 to 25 years who have been treated for neuroblastoma from January 1, 1998, to December 31, 2023. Participants will be asked to consent to the reuse of their data and complete a quality of life survey.
Who should consider this trial
Good fit: Ideal candidates are pediatric patients aged 2 to 25 years diagnosed with neuroblastoma and treated at the specified centers.
Not a fit: Patients with specific clinical forms of neuroblastoma or those receiving interfering treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the cost-effectiveness and quality of life outcomes associated with Dinutuximab treatment for neuroblastoma.
How similar studies have performed: While this study focuses on a specific cohort and treatment, similar observational studies have shown success in evaluating treatment outcomes and quality of life in pediatric oncology.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects aged 2 years to 25 years * Male or female gender * Subjects suffering from neuroblastoma and treated at the HUS or at the Oncopole center in Toulouse during the period from January 1, 1998 to December 31, 2023. * Subject (and/or holders of parental authority) not opposing, after information, the reuse of the child's data for the purposes of this research and agreeing to respond to the quality of life survey. Exclusion Criteria: * Patient or parents of the minor having expressed their opposition to participating in the study. * specific clinical forms of the disease, * interfering treatments and associated diseases.
Where this trial is running
Strasbourg
- Service de Pharmacie - Stérilisation - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Anne EL AATMANI, Pharm, PhD
- Email: Anne.ELAATMANI@chru-strasbourg.fr
- Phone: 33 3 88 12 78 06
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.